Comparing early versus later Impella CP pump use in heart attack with cardiogenic shock
Compares placing an Impella CP pump before or after stenting in cardiogenic shock.
Key facts
- Who runs it
- Chonnam National University Hospital
- Where
- Gwangju, South KoreaSee the site
- Trial code
- Registry title
- Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock
- Status
- Not yet recruiting
- People taking part
- 126 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 31 Jul 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Routine pre-PCI Impella CP
- Selective post-PCI Impella CP
- Record updated
- 14 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart attack and cardiogenic shock who need urgent artery-opening treatment (PCI) and are planned to get an Impella CP heart pump.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- Acute heart attack with cardiogenic shock before urgent PCI of the blocked artery. Left ventricular ejection fraction 40% or lower. Shock signs continue despite medical treatment. Shock began 12 hours or less before randomization.
- Earlier treatment
- Must not have had any mechanical circulatory support (such as a heart pump) before randomization.
- Biomarker or test result
- Left ventricular ejection fraction of 40% or lower.
Main reasons for not taking part
- Shock not caused by an acute heart attack, or no clear culprit lesion
- Mechanical complication of the heart attack
- Shock mainly of the right side or both sides of the heart
- Cardiac arrest that was not witnessed without bystander CPR, CPR longer than 45 minutes, or Glasgow Coma Scale below 8 after the heartbeat returned
- Active major bleeding, or cannot receive the blood-thinning medicines needed
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age ≥19 years old
- Acute myocardial infarction with culprit lesion requiring urgent percutaneous coronary intervention
- Cardiogenic shock before culprit lesion percutaneous coronary intervention
- Left ventricular ejection fraction ≤40%
- Patients with persistent signs of shock despite medical therapy who are scheduled to undergo Impella CP insertion
- Shock onset to randomization ≤12 hours
Who cannot take part
- Prior mechanical circulatory support before randomization
- Non-acute myocardial infarction-related shock
- Mechanical complication of myocardial infarction
- Refractory ventricular arrhythmia
- Unwitnessed cardiac arrest without bystander cardiopulmonary resuscitation
- Active major bleeding or inability to receive anticoagulation or antiplatelet therapy required for percutaneous coronary intervention and Impella CP support
- No clear culprit lesion
- Predominant right ventricular or biventricular shock
- Ongoing cardiopulmonary resuscitation at the time of screening
- Cardiopulmonary resuscitation duration >45 minutes
- Glasgow Coma Scale <8 after return of spontaneous circulation
- Contraindication to Impella CP use
- Life expectancy <1 year
Where in South Korea
- Chonnam National University HospitalGwangju, South KoreaContact: Min Chul KimNot yet recruiting
About the trial
What the trial wants to find out
PRIME-SHOCK is a prospective, single-center, open-label, randomized, superiority trial. Eligible participants with AMICS and a clinical decision to use Impella CP will be randomized in a 1:1 ratio before culprit-lesion PCI. The routine pre-PCI group will undergo Impella CP insertion immediately after allocation and before culprit-lesion PCI. The selective post-PCI group will undergo culprit-lesion PCI first; Impella CP will be inserted only if prespecified intra-procedural rescue criteria are met or shock persists or worsens after successful PCI. If all post-PCI recovery criteria are met, PCI will be concluded without Impella CP.
The 2 groups in the trial
- Routine pre-percutaneous coronary intervention (PCI) Impella CPTreatment being tested
In the pre-percutaneous coronary intervention (PCI) Impella CP group, Impella CP will be routinely inserted before culprit lesion PCI in patients with acute myocardial infarction-related cardiogenic shock.
Treatment: Routine pre-PCI Impella CP
- Selective post-percutaneous coronary intervention (PCI) Impella CPExisting treatment, for comparison
The selective post-percutaneous coronary intervention (PCI) Impella CP group will undergo culprit-lesion PCI first; Impella CP will be inserted only if prespecified intra-procedural rescue criteria are met or shock persists or worsens after successful PCI for culprit lesion.
Treatment: Selective post-PCI Impella CP
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Routine PRe-PCI Versus Selective Post-PCI Impella CP Management and Evaluation in Acute Myocardial Infarction-Related Cardiogenic SHOCK
- Plain-language title
- Comparing early versus later Impella CP pump use in heart attack with cardiogenic shockGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 14 September 2026